In a conversation with CancerNetwork®, Diane Simeone, MD, discussed the implications of daraxonrasib demonstrating meaningful improvements in survival among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the phase 3 RASolute 302 trial (NCT06625320). Topline findings from the trial showed that the novel multiselective RAS(ON) inhibitor approximately doubled the median overall survival (OS) compared with investigator’s choice of chemotherapy, with survival benefits extending to those with different RAS mutations and RAS wild-type disease.

Simeone spoke about the significance of these results in the context of the pancreatic cancer field, breaking down how daraxonrasib’s mechanism of action as a pan-RAS inhibitor may open a “new fronter” beyond standard-of-care chemotherapy and platinum-based regimens. She also touched upon the prominent toxicities that have emerged with daraxonrasib, including rashes, while emphasizing the balancing of risk and benefit as part of further optimizing RAS therapeutics.

The discussion also highlighted strategies for expanding genetic testing for patients with pancreatic cancer, as Simeone described the importance of receiving second opinions at comprehensive cancer centers where multidisciplinary teams can guide patients towards personalized treatment plans. She also mentioned how initiatives such as the Pancreatic Cancer Early Detection (PRECEDE) Consortium represent viable opportunities for continuing to elevate the quality of care for patients.

“This has been a Holy Grail type of thing, where people have been wanting to target KRAS but it’s been a challenge. This has been a breakthrough,” Simeone said regarding the results seen with daraxonrasib. “While the effect is dramatic in patients with metastatic cancer—and unfortunately that’s still half of patients who walk in the door with pancreatic cancer—applying this therapy to stage I cancer could be even more profound and drive cures. Investment in early detection, partnered with these advances in therapeutics, is where we will see the most significant progress in increasing survival rates.”

Simeone is the director of the Moores Cancer Center at University of California San Diego Health.

Reference

Daraxonrasib demonstrates unprecedented overall survival benefit in pivotal phase 3 RASolute 302 clinical trial in patients with metastatic pancreatic cancer. News release. Revolution Medicines. April 13, 2026. Accessed April 29, 2026. https://tinyurl.com/44t5vh5d